Tarik Asselah

Prof. Tarik Asselah


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
AMAbdellah Mansouri
Abdellah Mansouri
CGCharles-Henry Gattolliat
Charles-Henry Gattolliat
TATarik Asselah
Tarik Asselah

1 January 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
TATarik Asselah
Tarik Asselah
DDDavid Durantel
David Durantel
EPEric Pasmant
Eric Pasmant
GLGeorge Lau
George Lau
RSRaymond F. Schinazi
Raymond F. Schinazi

23 December 2013 in Liver International
Verified
Journal Article
Open access
PDF file
RSRaymond Schinazi
Raymond Schinazi
PHPhilippe Halfon
Philippe Halfon
PMPatrick Marcellin
Patrick Marcellin
TATarik Asselah
Tarik Asselah
For HCV infection, there have been major advancements during last several years with large numbers of ongoing trials with various direct‐acting antivirals (DAA) showing high potency, favourable tolerability profile, higher barrier to resistance, shortened treatment duration, all oral regimen, pan‐genotypic, fewer drug interactions and reduced pill burden. By 2014, several DAAs are anticipated to complete successful phase III trials and will be commercially available. Initially, a wave of IFN‐based regimen (sofosbuvir, faldaprevir and simeprevir) will be available for treatment of HCV genotype 1. In the near future, combination of antiviral agents with additive potency that lack cross‐resistance with good safety profile will likely be the new recommended regimens, making HCV, the first chronic viral infection to be eradicated worldwide with a finite duration of combination DAA therapy without IFN or ribavirin. The aim of this review was to summarize the results obtained from recent DAA combination studies without IFN.

1 March 2018 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
TATarik Asselah
Tarik Asselah
KKKris V. Kowdley
Kris V. Kowdley
NZNeddie Zadeikis
Neddie Zadeikis
SWStanley Wang
Stanley Wang
THTarek Hassanein
Tarek Hassanein
FMFederico J. Mensa
Federico J. Mensa

4 January 2016 in Liver International
Verified
Journal Article
Closed access
PDF file
TATarik Asselah
Tarik Asselah
NBNathalie Boyer
Nathalie Boyer
DSDavid SAADOUN
David SAADOUN
MMMichele Martinot‐Peignoux
Michele Martinot‐Peignoux
PMPatrick Marcellin
Patrick Marcellin

10 February 2018 in Liver International
Verified
Journal Article
Open access
PDF file
TATarik Asselah
Tarik Asselah
PMPatrick Marcellin
Patrick Marcellin
RSRaymond F. Schinazi
Raymond F. Schinazi
Around 71 million people are chronically infected with HCV worldwide. HCV antiviral drug development has been remarkable. The availability of pangenotypic direct‐acting antivirals with excellent efficacy and good tolerability profiles offer a unique opportunity to achieve HCV elimination worldwide. IFN‐free DAA combinations can now cure HCV in more than 95% of patients with HCV infection after 8‐12 weeks of treatment. Programmes to eliminate HCV must include increased screening (risk‐based and universal), linkage to care, as well as increased access to treatment worldwide. In this paper, we will review the available data on recently approved direct‐acting antiviral agents, with sustained virological response that reaches almost 100%.